Key Takeaways
- Transcranial magnetic stimulation (TMS) is an FDA-cleared neuromodulation technology that uses magnetic pulses to modulate activity in targeted brain regions without surgery or anesthesia.
- Deep TMS has received specific FDA clearance for reducing addictive behavior in adults with moderate to severe alcohol use disorder; it is the only form of brain stimulation with a specific addiction indication.
- Research on repetitive TMS for other substances including cocaine, methamphetamine, nicotine, and opioids shows promising results but awaits larger randomized controlled trials.
- TMS is most effective as an adjunct to comprehensive addiction treatment that includes medication-assisted treatment and behavioral therapy, not as a standalone intervention.
- The mechanism of TMS in addiction involves modulating prefrontal cortical activity to improve top-down control over subcortical reward circuits and reduce craving responses.
- Trust SoCal in Orange County coordinates with TMS providers and offers comprehensive addiction treatment that integrates all evidence-based modalities; call (949) 280-8360 for guidance.
Introduction: TMS as a Brain-Based Approach to Addiction
Transcranial magnetic stimulation represents one of the most scientifically grounded emerging approaches to addiction treatment precisely because its mechanism of action maps directly onto the well-established neuroscience of addiction. The core neuroscientific understanding of addiction identifies two key brain system dysfunctions: hyperactivity of subcortical reward circuits that amplifies the motivational salience of drug-related cues, and hypoactivity of prefrontal cortical regions that normally provide top-down inhibitory control over impulsive behavior. TMS can directly address the prefrontal component of this equation, applying targeted magnetic stimulation to the dorsolateral prefrontal cortex and other frontal regions to modulate their activity in ways that may reduce cravings and improve executive control.
Unlike pharmacological interventions that affect the entire brain through systemic administration, TMS delivers highly focused magnetic pulses to specific cortical regions through a coil placed against the scalp. These pulses induce electrical currents in targeted neurons, temporarily modulating their excitability and the activity of connected brain circuits. The directionality of the effect, whether increasing or decreasing cortical excitability, depends on the specific pattern of stimulation: high-frequency (10-20 Hz) repetitive TMS generally increases cortical excitability, while low-frequency (1 Hz) rTMS generally decreases it. Theta burst stimulation (TBS) protocols can achieve similar effects in much shorter treatment sessions, improving the practicality of TMS for clinical use.
The FDA clearance of deep TMS for alcohol use disorder in 2020 marked a regulatory milestone, establishing the first approved brain stimulation treatment for an addiction indication in the United States. This clearance was based on a well-designed randomized controlled trial demonstrating that deep TMS significantly reduced alcohol consumption in adults with moderate to severe alcohol use disorder. Trust SoCal in Fountain Valley monitors developments in TMS research and can provide guidance on how this technology might complement comprehensive addiction treatment. Contact us at (949) 280-8360.
FDA Clearance for Alcohol Use Disorder: The Evidence Base
The FDA clearance of the BrainsWay deep TMS system for alcohol use disorder was based primarily on a multicenter randomized controlled trial published in the American Journal of Psychiatry by Dinur-Klein and colleagues. The trial enrolled 131 adults with alcohol use disorder who were randomized to receive deep TMS targeting the medial prefrontal cortex and anterior cingulate cortex, or sham stimulation (where the coil is positioned to produce similar sensory experiences without delivering effective stimulation), administered three times per week for three weeks. Critically, the TMS was paired with cue-provocation, in which participants were exposed to alcohol-related cues before each stimulation session to activate the neural circuits targeted by the treatment.
The results showed that deep TMS significantly reduced the percentage of heavy drinking days and the percentage of days with any drinking at both a one-month and six-month follow-up compared to sham. Deep TMS also significantly reduced craving scores assessed immediately after cue exposure, suggesting that the treatment was directly modulating the cue-induced craving response. Biomarkers of alcohol consumption including gamma-glutamyl transpeptidase (GGT) and carbohydrate-deficient transferrin (CDT) showed corresponding improvements in the active TMS group, providing objective confirmation of self-reported reductions in drinking.
The FDA clearance specifies that the treatment is for adults with moderate to severe alcohol use disorder as an adjunct to other treatment, not as a standalone intervention. This adjunct designation is important: TMS does not replace the medications and behavioral therapies that form the foundation of evidence-based addiction treatment but rather complements them by directly modulating the prefrontal circuits that these other treatments also target through different mechanisms. The combination of pharmacological, behavioral, and neuromodulatory approaches may produce synergistic effects greater than any single modality.
Deep TMS is FDA-cleared (not just FDA-approved) for alcohol use disorder. FDA clearance means the device is substantially equivalent in safety and effectiveness to a legally marketed predicate device. This is a lower standard than the full FDA approval (premarket approval) required for novel drugs like esketamine.
Types of TMS Used in Addiction Research
Several different TMS technologies and protocols have been studied in addiction, each with distinct characteristics and applications.
- Standard rTMS: Uses a figure-8 coil to stimulate superficial cortical regions, typically the dorsolateral prefrontal cortex; stimulation depth limited to approximately 1-2 cm; most extensively studied TMS type in addiction research.
- Deep TMS (dTMS): Uses an H-coil (BrainsWay) that stimulates deeper cortical and subcortical regions, reaching 3-4 cm depth; FDA-cleared for alcohol use disorder and OCD; theoretically engages broader neural networks relevant to addiction.
- Theta Burst Stimulation (TBS): Delivers patterned bursts of high-frequency stimulation; achieves similar cortical effects to conventional rTMS in 3-minute sessions versus 30+ minutes; improving practical feasibility of TMS treatment.
- Paired Associative Stimulation (PAS): Pairs peripheral nerve stimulation with TMS to induce synaptic plasticity; under investigation for addiction but less developed than other approaches.
TMS Research for Other Substance Use Disorders
Beyond the FDA-cleared alcohol application, TMS has been investigated for a range of other substance use disorders with promising but less mature evidence. For cocaine use disorder, multiple randomized controlled trials have examined repetitive TMS applied to the left dorsolateral prefrontal cortex. A meta-analysis published in the Journal of Psychiatric Research found that rTMS significantly reduced cocaine craving compared to sham stimulation across seven studies, with moderate effect sizes. Interestingly, paired protocols that delivered TMS immediately before or during cue exposure showed larger craving reduction than unconditional TMS, suggesting that targeting the cue-reactivity mechanism specifically enhances effectiveness.
Research on TMS for methamphetamine use disorder, while more limited, has shown comparable findings. Studies from Iran and China, where methamphetamine use disorders are highly prevalent, have reported significant reductions in craving and improved abstinence outcomes with high-frequency rTMS to the dorsolateral prefrontal cortex compared to sham. A growing number of U.S.-based trials are now examining TMS for methamphetamine, driven by the urgent need for effective treatments given the absence of FDA-approved pharmacotherapies for stimulant use disorders. If these trials confirm preliminary findings, TMS could fill a critical gap in the stimulant addiction treatment toolkit.
For opioid use disorder, nicotine dependence, and cannabis use disorder, the TMS evidence base is at even earlier stages, with small pilot studies and inconsistent results. The most promising preliminary finding for opioid use disorder comes from research suggesting that TMS may reduce the affective component of pain, potentially addressing one of the key drivers of opioid use in individuals with chronic pain conditions. For nicotine, a 2019 meta-analysis found that rTMS significantly reduced nicotine craving and cigarette consumption, though effect sizes were smaller than those observed with pharmacotherapy. These findings are encouraging but require replication in larger, more rigorous trials.
TMS treatment for addiction typically involves 20-30 daily sessions over four to six weeks, with each session lasting 20-40 minutes depending on the protocol. Most patients find TMS well-tolerated; the most common side effects are mild scalp discomfort and headache at the stimulation site. Serious adverse effects including seizures are rare, occurring in less than 0.1% of courses.
How TMS Fits Into Comprehensive Addiction Treatment
Understanding the appropriate role of TMS in addiction treatment requires appreciating both its genuine promise and its current limitations. TMS is not a cure for addiction and is not designed to be used as a standalone treatment. Its mechanism of action, directly modulating prefrontal cortical excitability, complements but does not replace the pharmacological normalization of neurotransmitter systems achieved by medications like buprenorphine or naltrexone, or the behavioral circuit changes facilitated by CBT and contingency management. The most promising approach to TMS for addiction is integration within a comprehensive treatment plan that addresses multiple dimensions of the disorder simultaneously.
The cue-provocation paired TMS protocol, in which patients are exposed to substance-related cues before receiving TMS, represents a particularly elegant integration of TMS with established behavioral principles. This protocol mirrors the mechanism of cue exposure therapy, a behavioral intervention that extinguishes craving responses through repeated non-reinforced exposure to drug cues. By pairing cue exposure with TMS that modulates prefrontal cortical activity, the protocol may enhance the extinction of cue-triggered craving through both behavioral and neurophysiological mechanisms simultaneously. This kind of intelligent protocol design, targeting multiple mechanisms with complementary interventions, represents the future of addiction medicine.
For individuals seeking TMS as part of addiction treatment in Southern California, it is important to work with treatment providers who can coordinate TMS with other aspects of addiction care. A TMS course delivered in isolation, without accompanying medication management, behavioral therapy, and psychosocial support, is unlikely to produce durable recovery. Trust SoCal's clinical team can help patients evaluate whether TMS would be an appropriate adjunct to their treatment plan, provide referrals to TMS providers with experience in addiction, and ensure that TMS is integrated within rather than substituted for comprehensive addiction care. Contact us at (949) 280-8360 to discuss your options.
Candidates Most Likely to Benefit from TMS for Addiction
TMS for addiction is not appropriate for all patients; certain clinical characteristics suggest greater likelihood of benefit.
- Alcohol use disorder with moderate to severe symptom burden: The FDA-cleared indication; patients with significant prefrontal dysfunction and strong cue-reactivity may benefit most.
- Stimulant use disorder without approved pharmacotherapy: Patients with cocaine or methamphetamine use disorder who cannot achieve adequate control with behavioral therapy alone may represent an important candidate population given the absence of FDA-approved medications.
- Co-occurring treatment-resistant depression: TMS is FDA-approved for major depressive disorder; patients with comorbid depression and addiction may benefit from simultaneous targeting of both conditions.
- High cue-reactivity: Patients who report intense craving responses to substance-related cues, environmental triggers, or emotional states may derive particular benefit from cue-provocation paired TMS protocols.
Safety, Tolerability, and Practical Considerations
TMS has an excellent safety profile that distinguishes it favorably from many pharmacological interventions used in addiction treatment. The most common adverse effects of rTMS are mild to moderate scalp discomfort, headache, and occasionally muscle twitching at the stimulation site during sessions. These effects are typically well-tolerated and resolve promptly after sessions. Unlike medications, TMS does not produce systemic side effects including nausea, weight changes, sexual dysfunction, or liver toxicity. Unlike deep brain stimulation, TMS does not require surgery or implanted hardware. This favorable tolerability profile makes TMS an attractive option for patients who cannot tolerate or are unwilling to take medications.
The primary safety concern with TMS is the small risk of seizure, estimated at approximately 0.1 percent or less per treatment course with standard protocols. This risk is increased by certain factors including personal history of seizure disorder, concurrent use of medications that lower seizure threshold, and sleep deprivation. Proper screening for these risk factors before initiating TMS is essential. Relative contraindications include metallic implants in or near the head, including cochlear implants, deep brain stimulators, aneurysm clips, and some types of dental implants. Patients should disclose all medical devices and implants to TMS providers before beginning treatment.
Practical considerations for TMS in addiction treatment include the treatment duration (typically 20-30 daily sessions), the requirement to travel to a treatment facility for each session, cost (often $200-$400 per session without insurance, though FDA-cleared applications are increasingly covered), and the need to continue attending while maintaining early recovery. Some patients find the daily treatment schedule helpful in providing structure and professional contact during a vulnerable period; others find it burdensome. Trust SoCal can help patients navigate these practical considerations and identify TMS providers who offer addiction-specific protocols with appropriate clinical support. Call (949) 280-8360 for assistance.
The Future of TMS and Neuromodulation in Addiction
The future of TMS in addiction treatment is likely to be shaped by several converging developments: refinement of stimulation protocols through computational modeling of individual brain anatomy, integration of real-time neuroimaging feedback to guide stimulation parameters, combination with behavioral and pharmacological interventions in optimized multimodal protocols, and development of more practical delivery systems including wearable TMS devices that could make treatment more accessible. Neuroimaging-guided TMS, in which individual MRI scans are used to identify the optimal stimulation target based on each patient's specific brain anatomy and functional connectivity patterns, is already being implemented in some academic medical centers and has shown superior outcomes to standard target localization approaches.
Closed-loop TMS systems that monitor EEG or other neural signals in real-time and adjust stimulation parameters accordingly represent an exciting frontier. These systems could theoretically deliver stimulation precisely when cue-induced craving is detected and withdraw stimulation when the brain is in a more optimal state, maximizing therapeutic effect while minimizing unnecessary stimulation. While this technology is currently in the research domain, several companies are actively developing consumer-accessible neurostimulation devices, and the regulatory landscape will need to evolve to keep pace.
Trust SoCal in Fountain Valley, Orange County, remains committed to staying at the forefront of evidence-based addiction treatment, integrating new modalities as they achieve appropriate evidence bases and regulatory status. Our multidisciplinary team works closely with specialists across Southern California to ensure our patients can access the full spectrum of evidence-based care. Whether you are interested in currently available treatments or want to understand how emerging technologies might fit into your recovery plan, we are here to help. Visit us at 16537 Elm Cir, Fountain Valley, CA 92708, or call (949) 280-8360 to speak with our team.
TMS represents the convergence of addiction neuroscience and clinical practice. By directly targeting the prefrontal circuits compromised in addiction, we can complement medication and behavioral therapies in a way that addresses the neurobiological basis of impaired control.
— Neuromodulation research perspective in addiction psychiatry
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review